The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.
Human Rights Watch (HRW) claimed Thursday that the US government's decision to permit Lithium Americas to mine at Thacker Pass in Nevada violated Indigenous people's rights by failing to obtain ...
The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback